|Articles|September 20, 2018
OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research
Advertisement
Sorrento Therapeutics, Inc., a clinical stage, antibody-centric, biopharmaceutical company, has signed a new agreement with OmniComm Systems, Inc., a global provider of clinical data management technology, in which they will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Sorrento research sites.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Imfinzi Plus FLOT for Early and Locally Advanced Gastric and GEJ Cancers
2
Novo Nordisk Submits Higher-Dose Wegovy Injectable for FDA Approval with Priority Voucher
3
Is Artificial Intelligence Coming for Clinical Research?
4
FDA Clears Itvisma as First Gene Therapy for Adolescents and Adults With SMA
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
